Regulatory Intelligence
Mexico market entry · COFEPRIS strategy
Risk class determines evidence and timeline. Pathway selection determines whether the abbreviated route is realistic. Grouping determines the number of registrations. Dossier coherence determines whether the authority can review the case without contradiction. Registration holder strategy determines whether the manufacturer keeps market control.
95%+
Acceptance rate on registrations managed through Medisi’s strategic filing method.
The Federal Commission for Protection against Sanitary Risks is the Mexican health authority responsible for authorizing the commercialization of medical devices in the country. Without a Sanitary Registration — or, for low-risk devices, the corresponding Notice of Operation — a product cannot be legally imported, distributed, or sold in Mexico, nor can it participate in public health tenders.
COFEPRIS classifies medical devices into three risk-based classes, plus a specific category for software. Misclassifying a product — out of optimism or lack of knowledge — is one of the most common causes of deficiency letters and rejections. This isn’t an administrative detail: it determines which dossier, which evidence, and which timelines apply.
Class I
Low risk devices with extensive history of use.
Class II
Medium risk devices where clinical experience exists, but materials or use may vary.
Class III
High risk devices recently introduced or with significant impact on the body.
Software as a Medical Device
A specific category with dedicated documentation requirements.
Following the General Guidelines Agreement for the Abbreviated Regulatory Pathway, in effect since September 1, 2025, the landscape has been simplified to two pathways: the standard pathway and the fast-track equivalency pathway. Separate country-by-country routes no longer exist; everything was unified under a single equivalency-recognition criterion.
Standard Pathway
Sanitary Registration with a complete technical dossier, fully reviewed by COFEPRIS. It applies to any device, regardless of country of origin.
Fast-Track / Equivalency
Available only for devices with valid authorization from a reference regulatory authority in the IMDRF Management Committee, or an authority that is a full MDSAP member for Good Manufacturing Practice certificates. COFEPRIS targets a 30-calendar-day review window, but strategy still matters.
This is where strategy begins, before a single dossier document is drafted: does the product genuinely qualify for the fast-track pathway, with solid evidence and no changes relative to what the reference authority approved? Or is it better to go straight through the standard pathway to avoid objections that would extend the process longer than if it had been done correctly from the start?
Correctly classifying a product’s risk is only half of the diagnosis. The other half — and where most of a registration project’s budget is won or lost — is grouping: deciding which variants, models, presentations, or accessories within a product line can be combined into a single Sanitary Registration, and which require independent filings.
Over-grouping causes deficiency letters because the dossier loses coherence. Under-grouping multiplies filings, cost, and future maintenance burden. A serious market-entry diagnosis defines the correct number of registrations line by line of the manufacturer’s catalog — not one more, not one less.
It’s entirely possible to submit a dossier that, on paper, meets every requirement listed by COFEPRIS and still receive a deficiency letter. COFEPRIS doesn’t evaluate documents in isolation — it evaluates coherence. Risk classification, intended use, labeling, applicable standards, and clinical evidence all need to tell the same story, with no contradictions or ambiguity.
COFEPRIS does not always respond with the same criteria to the same type of dossier. Review times vary, and deficiency letters sometimes request clarifications that were not explicit in the regulation itself. That means a dossier that is “perfect on paper” is not a guarantee if it was not built to withstand regulatory variability.
The real difference between a firm that processes paperwork and one that designs strategy is how much friction it removes before the authority ever asks a question. Medisi’s system is built to reduce the wear and tear of dealing with an authority that is not always predictable.
Anticipate questions
Resolve ambiguous points before submission, not after COFEPRIS flags them.
Choose the pathway early
Select the correct regulatory route from the initial diagnosis, not by habit.
Minimize review cycles
Every round with the authority costs time, money, and institutional wear.
Build a technical narrative
The dossier should read as one coherent case, not a pile of annexes.
This approach is why Medisi maintains an acceptance rate above 95% on the registrations we manage. It is not luck, and it is not only accumulated experience — it is a method deliberately designed to reduce friction with an authority that, by its operational nature, is not always easy to predict.
A Sanitary Registration for a medical device in Mexico is first granted with a validity of five years, and the renewal application must be filed at least 150 days before the expiration date. As of January 2026, subsequent renewals can be granted for periods of up to ten years, reducing the ongoing administrative burden for products already established in the market.
One of the most costly mistakes manufacturers make is letting a first distributor file for and own the Sanitary Registration. If that relationship fails, switching distributors can mean starting the registration from scratch. The strategic alternative is for the manufacturer to retain regulatory control from day one, working with a specialized third party as the regulatory holder so distributors can sell under the authorization but never own it.
How long does it take to get a Sanitary Registration for a medical device in Mexico?
It depends on the risk class, the regulatory pathway chosen, and the quality of the dossier submitted. There is no single, legally guaranteed timeline — which is exactly why dossier strategy has such a large impact on actual resolution time.
What is the Abbreviated Regulatory Pathway?
It is the fast-track registration route, in effect since September 2025, available only for devices with prior authorization from a reference authority that is a member of the IMDRF Management Committee or a full member of MDSAP. It requires a correct diagnosis to confirm the product genuinely qualifies.
Do I need an Authorized Third Party, or can I file directly with COFEPRIS?
Both paths are legal. The difference usually lies in review times and technical support during the process, not in the final outcome of the filing itself.
What if my product already has FDA, Health Canada, or another IMDRF authority’s approval?
It may qualify for the fast-track equivalency pathway, provided the original approval was granted through a standard procedure, not emergency or conditional, and the summary dossier is built correctly.
How many registrations do I need if I have several variants of the same product?
It depends on grouping. If variants share intended use, technology, and risk profile, they can be combined into a single Sanitary Registration. If not, each one requires an independent filing.
Schedule a consultation with our team and enter Mexico with a dossier built as a regulatory case — not just a checklist.
Schedule a consultation